BMRN · Biomarin Pharmaceutical Inc
$67.36
-1.17 (-1.71%)
At close · Aug 14
Market Cap
$13.04B
Shares
193.57M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Alexander Hardy | President and CEO | $21,927,563 |
| Gregory Friberg | Executive Vice President, Chief Research & Development Officer — | $7,174,583 |
| Brian Mueller | Executive Vice President, CFO | $6,831,812 |
| Cristin Hubbard | Executive Vice President, Chief Commercial Officer — | $5,713,695 |
| C. Greg Guyer | Executive Vice President, Chief Technical Officer | $5,691,680 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Alexander Hardy | President and CEO — | $14,853,605 |
| Henry Fuchs | Former President, Worldwide Research & Development | $8,127,856 |
| Gregory Friberg | Executive Vice President, Chief Research & Development Officer — — | $7,221,559 |
| Cristin Hubbard | Executive Vice President, Chief Commercial Officer — — | $6,928,261 |
| Brian Mueller | Executive Vice President, CFO | $5,498,568 |
| G. Eric Davis | Executive Vice President, Chief Legal Officer | $5,058,665 |
| C. Greg Guyer | Executive Vice President, Chief Technical Officer | $5,057,033 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Jean-Jacques Bienaimé | Former CEO and Former Chairman of the Board | $21,976,020 |
| Alexander Hardy | President and CEO — | $17,875,236 |
| Henry Fuchs | Former President, Worldwide Research & Development | $9,660,818 |
| C. Greg Guyer | Executive Vice President, Chief Technical Officer | $5,701,119 |
| Jeff Ajer | Executive Vice President, Chief Commercial Officer | $5,070,357 |
| Brian Mueller | Executive Vice President, CFO | $4,854,192 |
| G. Eric Davis | Executive Vice President, Chief Legal Officer | $4,645,918 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Jean-Jacques Bienaimé | Former CEO and Former Chairman of the Board | $18,351,880 |
| Henry Fuchs | Former President, Worldwide Research & Development | $8,704,454 |
| Jeff Ajer | Executive Vice President, Chief Commercial Officer | $5,457,338 |
| G. Eric Davis | Executive Vice President, Chief Legal Officer | $5,189,142 |
| C. Greg Guyer | Executive Vice President, Chief Technical Officer | $5,109,550 |
| Brian Mueller | Executive Vice President, CFO | $5,107,284 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Jean-Jacques Bienaimé | Former CEO and Former Chairman of the Board | $18,262,538 |
| Henry Fuchs | President, Worldwide R&D | $6,929,366 |
| C. Greg Guyer | Executive Vice President, Chief Technical Officer | $5,427,248 |
| Jeff Ajer | Executive Vice President, Chief Commercial Officer | $4,985,408 |
| Brian Mueller | Executive Vice President, Finance and CFO | $4,699,165 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Jean-Jacques Bienaimé | CEO | $18,146,399 |
| Henry Fuchs | President, Worldwide R&D | $7,456,575 |
| C. Greg Guyer | Chief Technical Officer and Executive Vice President of Global Manufacturing and Technical Operations | $6,343,499 |
| Brian Mueller | Executive Vice President, Finance and CFO | $5,840,531 |
| Robert Baffi | Former President of Global Manufacturing and Technical Operations | $4,688,701 |
| Jeff Ajer | Executive Vice President, Chief Commercial Officer | $4,536,436 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Jean-Jacques Bienaimé | CEO | $18,405,856 |
| Henry Fuchs | President, Worldwide R&D | $7,017,499 |
| Robert Baffi | Former President of Global Manufacturing and Technical Operations | $6,503,503 |
| Jeff Ajer | Executive Vice President, Chief Commercial Officer | $6,344,322 |
| Daniel Spiegelman | Former Executive Vice President, Chief Financial Officer | $5,239,902 |
| Brian Mueller | Executive Vice President, Finance and CFO | $1,676,536 |
| C. Greg Guyer | Chief Technical Officer and Executive Vice President of Global Manufacturing and Technical Operations | — |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Jean-Jacques Bienaimé | Chief Executive Officer | $15,627,893 |
| Henry Fuchs | President, Worldwide R&D | $5,777,729 |
| Jeff Ajer | Executive Vice President, Chief Commercial Officer | $4,545,383 |
| Daniel Spiegelman | Former Executive Vice President, Chief Financial Officer | $4,521,703 |
| Robert Baffi | Former President of Global Manufacturing and Technical Operations | $4,427,918 |
| Brian Mueller | Executive Vice President and Chief Financial Officer Daniel Spiegelman Former Executive Vice President, Chief Financial Officer | $1,524,685 |
| C. Greg Guyer | Chief Technical Officer and Executive Vice President of Global Manufacturing and Technical Operations | — |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Jean-Jacques Bienaimé | Chief Executive Officer | $15,916,985 |
| Henry Fuchs | President, Worldwide R&D | $7,045,424 |
| Daniel Spiegelman | Former Executive Vice President, Chief Financial Officer | $4,641,875 |
| Jeff Ajer | Executive Vice President, Chief Commercial Officer | $4,568,302 |
| Robert Baffi | President, Global Manufacturing & Technical Operations | $4,473,228 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Rashmi Ramchandani | Vice President, Chief Accounting Officer | Appointed | 2025-12-17 |
| Erin Burkhart | Group Vice President, Chief Accounting Officer and principal accounting officer | Resigned | 2025-08-11 |
| Ian T. Clark | to the Board | Appointed | 2025-08-01 |
| Timothy P. Walbert | Director | Appointed | 2025-02-24 |
| Dr. Henry J. Fuchs | his current role | Retired | 2024-08-22 |
| Jeffrey Ajer | Executive Vice President and Chief Commercial Officer | Terminated | 2024-01-11 |
| Mark Enyedy | independent director | Appointed | 2023-12-20 |
| Athena Countouriotis | independent director | Appointed | 2023-12-20 |
| Barbara Bodem | independent director | Appointed | 2023-12-20 |
| Alexander Hardy | member of the Board | Appointed | 2023-11-03 |
| Richard A. Meier | Chair of the Board | Appointed | 2023-11-03 |
| Alexander Hardy | President and Chief Executive Officer | Appointed | 2023-11-03 |
| Jean-Jacques Bienaimé | Chairman | Retired | 2023-11-03 |
| Jean-Jacques Bienaimé | President, Chairman and Chief Executive Officer | Retired | 2023-11-03 |
| Dennis J. Slamon, M.D., Ph.D. | Director | Appointed | 2023-05-30 |
| David E.I. Pyott, M.D. (Hon.) | Director | Appointed | 2023-05-30 |
| Maykin Ho, Ph.D. | Director | Appointed | 2023-05-30 |
| V. Bryan Lawlis, Ph.D. | Director | Appointed | 2023-05-30 |
| Richard A. Meier | Director | Appointed | 2023-05-30 |
| Robert J. Hombach | Director | Appointed | 2023-05-30 |
| Elaine J. Heron, Ph.D. | Director | Appointed | 2023-05-30 |
| Jean-Jacques Bienaimé | Director | Appointed | 2023-05-30 |
| Willard Dere, M.D. | Director | Appointed | 2023-05-30 |
| Elizabeth McKee Anderson | Director | Appointed | 2023-05-30 |
| Mark J. Alles | Director | Appointed | 2023-05-30 |
Key facts
CIK
1048477
CUSIP
09061G101
13F (30d)
543 filings
511 filers
Visit website
Investor relations